Audrey Kunin - Nov 21, 2022 Form 4/A - Amendment Insider Report for NovaBay Pharmaceuticals, Inc. (NBY)

Role
Chief Product Officer
Signature
/s/ Audrey Kunin
Stock symbol
NBY
Transactions as of
Nov 21, 2022
Transactions value $
-$12,545
Form type
4/A - Amendment
Date filed
12/5/2022, 04:30 PM
Date Of Original Report
Nov 23, 2022
Previous filing
Sep 16, 2022
Next filing
Dec 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBY Common Stock Sale -$12.5K -5.96K -99.98% $2.10 1 Nov 21, 2022 See footnote F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 15, 2022, the common stock of NovaBay Pharmaceuticals, Inc. split 1-for-35, and is reflected accordingly in the number of shares sold.
F2 This transaction was executed in multiple trades at prices ranging from $2.09 to $2.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The original Form 4, filed on November 23, 2022, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported that the reporting person beneficially owned no shares following the reported transaction when in fact the reporting person beneficially owned one share following the reported transaction.
F4 By The Audrey G. Kunin Trust in which the reporting person serves as the trustee and has investment control.